Why Is Amkor Stock Up So Much?
Semiconductor packaging and testing major Amkor (NASDAQ:AMKR) has started 2026…
Buy
54
SRNE Quote, Financials, Valuation and Earnings
Last price:
$0.0000
Seasonality move
:
42.73%
Day range:
$0.0025 - $0.0037
52-week range:
$0.0001 - $0.0985
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.02x
P/B ratio:
--
Volume:
22.6K
Avg. volume:
582.5K
1-year change:
520%
Market cap:
$1.7M
Revenue:
--
EPS (TTM):
--
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Sorrento Therapeutics, Inc. has 419254.84% upside to fair value with a price target of -- per share.
SRNE vs. S&P 500
-
Over the past 5 trading days, Sorrento Therapeutics, Inc. has underperformed the S&P 500 by -3.11% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Sorrento Therapeutics, Inc. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Sorrento Therapeutics, Inc. has grown year-over-year revenues for 1 quarter straight. In the most recent quarter Sorrento Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Sorrento Therapeutics, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Sorrento Therapeutics, Inc. reported earnings per share of --.
Enterprise value:
135.8M
EV / Invested capital:
--
Price / LTM sales:
0.02x
EV / EBIT:
--
EV / Revenue:
2.11x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.56x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2022-06-30 | 2023-06-30 | |
| Income Statement | ||||||
| Revenue | $51M | $55M | $64.3M | $11.5M | $15M | |
| Gross Profit | $39.3M | $30.8M | $24.1M | $4.7M | $5.4M | |
| Operating Income | -$288.4M | -$383.7M | -$355.5M | -$91.9M | -$76.8M | |
| EBITDA | -$303.3M | -$366.2M | -$336.1M | -$87.5M | -$71.1M | |
| Diluted EPS | -$1.14 | -$1.53 | -$1.06 | -$0.54 | -$0.17 | |
| Period Ending | 2019-06-30 | 2020-06-30 | 2021-06-30 | 2022-06-30 | 2023-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $93.5M | $55M | $155.3M | $196M | $133.1M | |
| Total Assets | $587M | $533.1M | $778.9M | $632.1M | $456.7M | |
| Current Liabilities | $112M | $91.3M | $180.5M | $145.3M | $264.9M | |
| Total Liabilities | $532.4M | $452.9M | $593.4M | $496.4M | $654.6M | |
| Total Equity | $54.6M | $80.2M | $185.5M | $135.8M | -$198M | |
| Total Debt | $255.8M | $166.2M | $112.4M | $191.1M | $194.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2022-06-30 | 2023-06-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$210M | -$319.6M | -$234.6M | -$81M | -$55.7M | |
| Cash From Investing | $40M | -$12.2M | -$11.6M | -$1.7M | -$140K | |
| Cash From Financing | $176.7M | $326.1M | $246.6M | $41.8M | $88.8M | |
| Free Cash Flow | -$221.1M | -$328.3M | -$243.2M | -$83.7M | -$55.8M | |
SRNE
Sector
Market Cap
$1.7M
$28.1M
Price % of 52-Week High
3.15%
51.87%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.59%
1-Year Price Total Return
520%
-17.31%
Beta (5-Year)
1.234
0.495
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$0.0028
200-day SMA
Sell
Level
$0.0033
Bollinger Bands (100)
Sell
Level
0.0049 - 0.0049
Chaikin Money Flow
Sell
Level
-1M
20-day SMA
Sell
Level
$0.0031
Relative Strength Index (RSI14)
Sell
Level
48.0443
ADX Line
Buy
Level
21.6612
Williams %R
Neutral
Level
-71.134
50-day SMA
Sell
Level
$0.0051
MACD (12, 26)
Buy
Level
0.0007
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Sell
Level
-1.7M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Sorrento Therapeutics, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It operates through the Sorrento Therapeutics and Scilex segments. The Sorrento Therapeutics segment consists of developing a portfolio of next generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. The Scilex segment is largely organized around the company's non-opioid pain management operations. The company was founded by Henry H. Ji in 1989 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, SRNE has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SRNE average analyst price target in the past 3 months is --.
-
Where Will Sorrento Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Sorrento Therapeutics, Inc. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Sorrento Therapeutics, Inc.?
Analysts are divided on their view about Sorrento Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sorrento Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to --.
-
What Is Sorrento Therapeutics, Inc.'s Price Target?
The price target for Sorrento Therapeutics, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SRNE A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Sorrento Therapeutics, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of SRNE?
You can purchase shares of Sorrento Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sorrento Therapeutics, Inc. shares.
-
What Is The Sorrento Therapeutics, Inc. Share Price Today?
Sorrento Therapeutics, Inc. was last trading at $0.0000 per share. This represents the most recent stock quote for Sorrento Therapeutics, Inc.. Yesterday, Sorrento Therapeutics, Inc. closed at $0.0031 per share.
-
How To Buy Sorrento Therapeutics, Inc. Stock Online?
In order to purchase Sorrento Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get SRNE Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SRNE
Sector
P/E ratio
--
24.20x
PEG ratio
--
-0.01x
P/B ratio
--
1.84x
Price / LTM sales
0.02x
1.60x
Growth Metrics
SRNE
Sector
Revenue growth
--
4.51%
Earnings growth
--
10.7%
Revenue (5-year growth)
--
6.45%
Earnings forecast
--
-$0.19
Profitability
SRNE
Sector
Profitability FY 2025
--
$3.5M
Return on invested capital
--
-32.3%
Return on assets
--
-28.57%
Return on equity
--
-38.09%
Earnings Date
Last Earnings Date
Nov
22
Next Earnings Date
Jan
11
Estimated Next Earnings Date
Apr
12
Balance Sheet
SRNE
Sector
Total cash
--
$26M
Short term investments
--
$25.7M
Total assets
--
$76.4M
Long term debt
--
$3.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
